Background
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.• Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation., PMID:29482174• The low density lipoprotein receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and down-regulates the canonical Wnt signaling pathway., PMID:14739301• Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway., PMID:22484497• Functional and association analysis of frizzled 1 (FZD1) promoter haplotypes with femoral neck geometry., PMID:20051274• Functional characterization of genetic variation in the Frizzled 1 (FZD1) promoter and association with bone phenotypes: more to the LRP5 story?, PMID:18715140• Transcriptional Regulation of Frizzled-1 in Human Osteoblasts by Sp1., PMID:27695039• Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response., PMID:10557084• Oligodendroglial ring finger protein Rnf43 is an essential injury-specific regulator of oligodendrocyte maturation., PMID:34390652• miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1., PMID:27643554• FZD1 activates protein kinase C delta-mediated drug-resistance in multidrug-resistant MES-SA/Dx5 cancer cells., PMID:24814288